BioAtla Investor Presentation Deck

Many key milestones and catalysts throughout 2023 Submit BA3011 Exposure-Response analysis to medical meeting FPI BA3021 SCCHN Phase 2 1H Initiate BA3182 Phase 1 study Enrolling more frequent dosing regimens in BA3011 NSCLC Phase 2, part 1 FPI BA3011 UPS Phase 2, part 2 potentially registrational study Request FDA feedback re: BA3011 NSCLC Phase 2, part 2 potentially registrational study design FPI BA3021 NSCLC Phase 2 more frequent dosing regimens bicatla *Phase 2 Investigator-initiated trial combination with PD-1 (n=20) in platinum failure patients. FPI, First Patient In; LMS, Leiomyosarcoma 2023 Receive FDA feedback re: BA3011 NSCLC Phase 2, part 2 potentially registrational study design Initiate BA3011 NSCLC Phase 2, part 2 potentially registrational study 2H Prioritize BA3021 registration indications BA3071 Phase 1 data Initiate BA3071 Phase 2 study BA3011 Phase 2, part 1 LMS data BA3011 Phase 2 IIT* interim data (n=10) in platinum-resistant ovarian cancer BA3021 Phase 2 IIT* interim data (n=10) in platinum-resistant ovarian cancer BioAtla| Overview 41

View entire presentation